Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the li
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.